Any handicapped persons requiring special accommodations in order to attend the hearing should inform the contact person listed in order for FDA to be prepared to meet those needs.

To the extent that the conditions for the hearing as described in this notice, conflict with any provisions set out in part 15, this notice acts as a waiver of those provisions as specified in § 15.30(h)

Dated: July 10, 1995.

William B. Schultz,

Deputy Commissioner for Policy.

[FR Doc. 95–17535 Filed 7–17–95; 8:45 am]

BILLING CODE 4160–01–F

[Docket No. 95F–0174]

H.B. Fuller Co.; Filing of Food Additive Petition

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is announcing that H.B. Fuller Co. has filed a petition proposing that the food additive regulations be amended to provide for the safe use of nonanoic acid, lactic acid, citric acid, sodium 1-octane sulfonate, tertiary butylhydroquinone, and the sodium salt of tetrapropylene-1,1-oxybis-benzenesulfonic acid as components of a sanitizing solution intended for general use on food-contact surfaces.

DATES: Written comments on the petitioner's environmental assessment by August 17, 1995.

ADDRESSES: Submit written comments to the Dockets Management Branch (HFA–305), Food and Drug Administration, rm. 1–23, 12420 Parklawn Dr., Rockville, MD 20857.

FOR FURTHER INFORMATION CONTACT: Diane E. Robertson, Center for Food Safety and Applied Nutrition (HFS–216), Food and Drug Administration, 200 C St. SW., Washington, DC 20204, 202–418–3089.

SUPPLEMENTARY INFORMATION: Under the Federal Food, Drug, and Cosmetic Act (sec. 409(b)(5) (21 U.S.C. 348(b)(5))), notice is given that a food additive petition (FAP 5B4462) has been filed by H.B. Fuller Co., c/o SRS International Corp., 1625 K St. NW., suite 1000, Washington, DC 20006–1604. The petition proposes to amend the food additive regulations in § 178.1010 *Sanitizing solutions* (21 CFR 178.1010) to provide for the safe use of nonanoic acid, lactic acid, citric acid, sodium 1-octane sulfonate, tertiary butylhydroquinone, and the sodium salt of tetrapropylene-1,1-oxybis-benzenesulfonic acid as components of a sanitizing solution intended for general use on food-contact surfaces.

The potential environmental impact of this action is being reviewed. To encourage public participation consistent with regulations promulgated under the National Environmental Policy Act (40 CFR 1501.4(b)), the agency is placing the environmental assessment submitted with the petition that is the subject of this notice on public display at the Dockets Management Branch (address above) for public review and comment. Interested persons may, on or before August 17, 1995, submit to the Dockets Management Branch (address above) written comments. Two copies of any comments are to be submitted, except that individuals may submit one copy. Comments are to be identified with the docket number found in brackets in the heading of this document. Received comments may be seen in the office above between 9 a.m. and 4 p.m., Monday through Friday. FDA will also place on public display any amendments to, or comments on, the petitioner's environmental assessment without further announcement in the **Federal Register**. If, based on its review, the agency finds that an environmental impact statement is not required and this petition results in a regulation, the notice of availability of the agency's finding of no significant impact and the evidence supporting that finding will be published with the regulation in the **Federal Register** in accordance with 21 CFR 25.40(c).

Dated: July 5, 1995.

Alan M. Rulis,

Acting Director, Office of Premarket Approval, Center for Food Safety and Applied Nutrition.

[FR Doc. 95–17639 Filed 7–17–95; 8:45 am]

BILLING CODE 4160–01–F

[Docket No. 95N–0206]

Richmar International, Inc., et al.; Withdrawal of Approval of 2 Abbreviated Antibiotic Applications and 15 Abbreviated New Drug Applications

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is withdrawing approval of 2 abbreviated antibiotic applications (AADA's) and 15 abbreviated new drug applications (ANDA's). The holders of the applications notified the agency in writing that the drug products were no longer marketed and requested that the approval of the applications be withdrawn.

EFFECTIVE DATE: AUGUST 17, 1995.

FOR FURTHER INFORMATION CONTACT: Lola E. Batson, Center for Drug Evaluation and Research (HFD–360), Food and Drug Administration, 7500 Standish Pl., Rockville, MD 20855, 301–594–1038.

SUPPLEMENTARY INFORMATION: The holders of the applications listed in the table in this document have informed FDA that these drug products are no longer marketed and have requested that FDA withdraw approval of the applications. The applicants have also, by their request, waived their opportunity for a hearing.

Application No.	Drug	Applicant
AADA 60–446.	Tetracycline Oral Suspension, U.S.P	Richmar International, Inc., 1706 Birch Rd., McLean, VA 22101.
AADA 62–502.	Nystatin Vaginal Tablets, U.S.P., 100,000 units	Lemmon Co., 650 Cathill Rd., Sellersville, PA 18960.
ANDA 70–438.	Propranolol Hydrochloride Tablets, U.S.P., 10milligrams (mg)	Warner Chilcott, 201 Tabor Rd., Morris Plains, NJ 07950.
ANDA 70–439.	Propranolol Hydrochloride Tablets, U.S.P., 20 mg	Do.
ANDA 70–440.	Propranolol Hydrochloride Tablets, U.S.P., 40 mg	Do.
ANDA 70–441.	Propranolol Hydrochloride Tablets, U.S.P., 60 mg	Do.